Literature DB >> 9712026

A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement.

R Siefken1, S Klein-Hessling, E Serfling, R Kurrle, R Schwinzer.   

Abstract

Stimulation of resting human T cells with the CD28-specific mAb BW 828 induces proliferation and cytokine synthesis without further requirement for TCR coengagement. This observation prompted us to postulate that signal 2 (costimulatory signal) alone without signal 1 (TCR signal) can activate T cells. To test whether this putative function of CD28 is mediated via a particular signaling pathway, we compared early signaling events initiated in resting T cells by the stimulatory mAb BW 828 with signals triggered by the nonstimulating CD28 mAb 9.3. Stimulation of T cells with BW 828 induced an increase in intracellular Ca2+, but did not lead to detectable activation of the protein kinases p56(lck) and c-Raf-1. This pathway resulted in the induction of the transcription factors NF-kappa B, NF-AT, and proteins binding to the CD28 response element of the IL-2 promoter. On the other hand, stimulation of T cells with mAb 9.3 increased the level of intracellular Ca2+ and triggered the activation of p56(lck) and c-Raf-1, but was unable to induce the binding of transcription factors to the IL-2 promoter. In contrast to the differential signaling of BW 828 and 9.3 in resting T cells, the two mAbs exhibited a similar pattern of early signaling events in activated T cells and Jurkat cells (p56(lck) activation, association of phosphatidylinositol 3-kinase with CD28), indicating that the signaling capacity of CD28 changes with activation. These data support the view that stimulation through CD28 can induce some effector functions in T cells and suggest that this capacity is associated with a particular pattern of early signaling events.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712026

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.

Authors:  Manisha Singh; Sreemanti Basu; Christina Camell; Jacob Couturier; Rodolfo J Nudelman; Miguel A Medina; John R Rodgers; Dorothy E Lewis
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

2.  Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor alpha-chain locus.

Authors:  J H Yeh; P Lecine; J A Nunes; S Spicuglia; P Ferrier; D Olive; J Imbert
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

3.  Robust T cell activation requires an eIF3-driven burst in T cell receptor translation.

Authors:  Dasmanthie De Silva; Lucas Ferguson; Grant H Chin; Benjamin E Smith; Ryan A Apathy; Theodore L Roth; Franziska Blaeschke; Marek Kudla; Alexander Marson; Nicholas T Ingolia; Jamie Hd Cate
Journal:  Elife       Date:  2021-12-31       Impact factor: 8.140

4.  Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.

Authors:  Fred Lühder; Yun Huang; Kevin M Dennehy; Christine Guntermann; Ingrid Müller; Erna Winkler; Thomas Kerkau; Shinji Ikemizu; Simon J Davis; Thomas Hanke; Thomas Hünig
Journal:  J Exp Med       Date:  2003-04-21       Impact factor: 14.307

5.  Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes.

Authors:  G Woerly; N Roger; S Loiseau; D Dombrowicz; A Capron; M Capron
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

6.  A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.

Authors:  Aruto Sugiyama; Mitsuo Umetsu; Hikaru Nakazawa; Teppei Niide; Tomoko Onodera; Katsuhiro Hosokawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

7.  Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.

Authors:  Zoe Waibler; Linda Y Sender; Camilla Merten; Roland Hartig; Stefanie Kliche; Matthias Gunzer; Peter Reichardt; Ulrich Kalinke; Burkhart Schraven
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.